Protagenic's Neuropeptide Shows Strong Efficacy in Treating Depression and Anxiety of Established Rodent Models

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /><ul type="disc"><li>First in class psychotropic agent</li><li>50% reduction in anxiety related symptoms</li><li>Data generated by independent world-renowned laboratory</li></ul><p align="justify">NEW YORK, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (OTCQB:PTIX) announced today that experiments conducted at independent contract research...